# Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal

> **NCT07155122** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Small-Cell Carcinoma of the Esophageal

## Interventions

- **DRUG:** Drug: Serplulimab
- **DRUG:** Drug: Etoposide
- **DRUG:** Drug: Chemotherapy

## Key facts

- **NCT ID:** NCT07155122
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155122, "Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07155122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*